MiNK Therapeutics (INKT) Competitors $7.72 +0.27 (+3.62%) Closing price 03:58 PM EasternExtended Trading$7.86 +0.14 (+1.81%) As of 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock INKT vs. ENTA, EDIT, NLTX, PROC, NMRA, LXEO, TIL, SNTI, RAPT, and TNXPShould you be buying MiNK Therapeutics stock or one of its competitors? The main competitors of MiNK Therapeutics include Enanta Pharmaceuticals (ENTA), Editas Medicine (EDIT), Neoleukin Therapeutics (NLTX), Procaps Group (PROC), Neumora Therapeutics (NMRA), Lexeo Therapeutics (LXEO), Instil Bio (TIL), Senti Biosciences (SNTI), RAPT Therapeutics (RAPT), and Tonix Pharmaceuticals (TNXP). These companies are all part of the "pharmaceutical products" industry. MiNK Therapeutics vs. Enanta Pharmaceuticals Editas Medicine Neoleukin Therapeutics Procaps Group Neumora Therapeutics Lexeo Therapeutics Instil Bio Senti Biosciences RAPT Therapeutics Tonix Pharmaceuticals Enanta Pharmaceuticals (NASDAQ:ENTA) and MiNK Therapeutics (NASDAQ:INKT) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, community ranking, institutional ownership, earnings, media sentiment and analyst recommendations. Is ENTA or INKT more profitable? MiNK Therapeutics has a net margin of 0.00% compared to Enanta Pharmaceuticals' net margin of -157.57%. MiNK Therapeutics' return on equity of 0.00% beat Enanta Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Enanta Pharmaceuticals-157.57% -75.53% -27.30% MiNK Therapeutics N/A N/A -189.14% Do institutionals and insiders hold more shares of ENTA or INKT? 95.0% of Enanta Pharmaceuticals shares are owned by institutional investors. Comparatively, 2.9% of MiNK Therapeutics shares are owned by institutional investors. 13.9% of Enanta Pharmaceuticals shares are owned by company insiders. Comparatively, 20.6% of MiNK Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Which has better earnings and valuation, ENTA or INKT? MiNK Therapeutics has lower revenue, but higher earnings than Enanta Pharmaceuticals. MiNK Therapeutics is trading at a lower price-to-earnings ratio than Enanta Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEnanta Pharmaceuticals$66.59M1.94-$116.04M-$4.95-1.22MiNK TherapeuticsN/AN/A-$22.46M-$2.92-2.64 Does the media refer more to ENTA or INKT? In the previous week, Enanta Pharmaceuticals had 4 more articles in the media than MiNK Therapeutics. MarketBeat recorded 5 mentions for Enanta Pharmaceuticals and 1 mentions for MiNK Therapeutics. MiNK Therapeutics' average media sentiment score of 1.87 beat Enanta Pharmaceuticals' score of 0.93 indicating that MiNK Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Enanta Pharmaceuticals Positive MiNK Therapeutics Very Positive Does the MarketBeat Community believe in ENTA or INKT? Enanta Pharmaceuticals received 303 more outperform votes than MiNK Therapeutics when rated by MarketBeat users. However, 77.27% of users gave MiNK Therapeutics an outperform vote while only 56.94% of users gave Enanta Pharmaceuticals an outperform vote. CompanyUnderperformOutperformEnanta PharmaceuticalsOutperform Votes32056.94% Underperform Votes24243.06% MiNK TherapeuticsOutperform Votes1777.27% Underperform Votes522.73% Do analysts rate ENTA or INKT? Enanta Pharmaceuticals currently has a consensus target price of $17.25, suggesting a potential upside of 185.12%. MiNK Therapeutics has a consensus target price of $37.50, suggesting a potential upside of 385.75%. Given MiNK Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe MiNK Therapeutics is more favorable than Enanta Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Enanta Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.80MiNK Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more risk and volatility, ENTA or INKT? Enanta Pharmaceuticals has a beta of 0.69, meaning that its share price is 31% less volatile than the S&P 500. Comparatively, MiNK Therapeutics has a beta of 0.15, meaning that its share price is 85% less volatile than the S&P 500. SummaryEnanta Pharmaceuticals and MiNK Therapeutics tied by winning 9 of the 18 factors compared between the two stocks. Get MiNK Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for INKT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INKT vs. The Competition Export to ExcelMetricMiNK TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$30.62M$2.96B$5.49B$7.95BDividend YieldN/A1.89%5.11%4.22%P/E Ratio-1.9830.2822.6218.58Price / SalesN/A496.13397.85103.49Price / CashN/A168.6838.1834.62Price / Book-1.483.176.744.25Net Income-$22.46M-$72.35M$3.22B$248.18M7 Day Performance3.35%0.96%1.59%1.36%1 Month Performance-16.27%8.29%4.09%3.85%1 Year Performance-18.95%-22.57%15.98%5.37% MiNK Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INKTMiNK Therapeutics2.7645 of 5 stars$7.72+3.6%$37.50+385.8%-23.5%$30.62MN/A-1.9830Positive NewsENTAEnanta Pharmaceuticals3.9335 of 5 stars$5.23+2.5%$17.25+229.8%-55.7%$111.57M$66.59M-1.06160Upcoming EarningsNews CoverageGap DownEDITEditas Medicine4.1576 of 5 stars$1.33+3.9%$6.83+413.8%-68.3%$111.33M$32.31M-0.52230Upcoming EarningsAnalyst UpgradeAnalyst RevisionNews CoverageNLTXNeoleukin TherapeuticsN/A$11.49+6.7%N/A-61.0%$107.98MN/A-3.6990Gap DownHigh Trading VolumePROCProcaps GroupN/A$0.95-40.3%N/A-66.4%$107.18M$409.92M0.004,900Gap DownHigh Trading VolumeNMRANeumora Therapeutics3.139 of 5 stars$0.66+2.0%$9.29+1,306.9%-91.4%$106.75MN/A-0.35108LXEOLexeo Therapeutics2.5326 of 5 stars$3.21+18.5%$22.20+591.6%-68.4%$106.56M$650,000.00-1.0258Upcoming EarningsPositive NewsHigh Trading VolumeTILInstil Bio3.3766 of 5 stars$16.00+3.6%$114.00+612.5%+18.8%$104.94MN/A-1.38410Positive NewsSNTISenti Biosciences2.8608 of 5 stars$3.97+2.3%$10.00+151.9%-7.8%$103.24M$2.56M-0.264Upcoming EarningsNews CoverageRAPTRAPT Therapeutics4.156 of 5 stars$0.78-1.1%$4.00+411.5%-88.0%$103.23M$1.53M-0.2880Upcoming EarningsShort Interest ↓News CoveragePositive NewsTNXPTonix Pharmaceuticals2.2433 of 5 stars$14.96-4.8%$585.00+3,810.4%-96.9%$101.09M$10.09M0.0050Short Interest ↑ Related Companies and Tools Related Companies Enanta Pharmaceuticals Competitors Editas Medicine Competitors Neoleukin Therapeutics Competitors Procaps Group Competitors Neumora Therapeutics Competitors Lexeo Therapeutics Competitors Instil Bio Competitors Senti Biosciences Competitors RAPT Therapeutics Competitors Tonix Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:INKT) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeWhile everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredTrump announcement boosts “next Bitcoin”President Trump just made his first big crypto move ... Announcing the creation of a national strategic re...Weiss Ratings | SponsoredThis Is How Empires FallThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MiNK Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MiNK Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy INKT Stock Free INKT Stock Alerts